Content about Dementia

March 26, 2014

Early-stage Alzheimer’s disease, or AD, increasingly is the target of drug development efforts, but there are very few tools that measure the cognitive function of patients with the condition before the onset of dementia. Experts have concluded that it is best to treat patients prior to changes in cognition, before the symptoms of neurodegeneration appear. As a result, scientists have turned to biomarkers to provide some indication of whether AD is likely to develop.

Early-stage Alzheimer’s disease, or AD, increasingly is the target of drug development efforts, but there are very few tools that measure the cognitive function of patients with the condition before the onset of dementia. Experts have concluded that it is best to treat patients prior to changes in cognition, before the symptoms of neurodegeneration appear. As a result, scientists have turned to biomarkers to provide some indication of whether AD is likely to develop.

January 2, 2014

Among patients with mild to moderate Alzheimer disease, a daily dosage of 2,000 IUs of vitamin E, compared to placebo, was effective in slowing functional decline and in reducing caregiver time in assisting patients, according to a study that appeared in the Jan. 1 issue of JAMA.

CHICAGO — Among patients with mild to moderate Alzheimer disease, a daily dosage of 2,000 IUs of vitamin E, compared to placebo, was effective in slowing functional decline and in reducing caregiver time in assisting patients, according to a study that appeared in the Jan. 1 issue of the Journal of the American Medical Association.

July 8, 2013

More than half of the estimated 5.4 million Americans with Alzheimer's disease and other forms of dementia are at risk of wandering and becoming lost, according to the National Institute on Aging, a figure that has prompted the federal government to develop a series of training videos for police.

WASHINGTON — More than half of the estimated 5.4 million Americans with Alzheimer's disease and other forms of dementia are at risk of wandering and becoming lost, according to the National Institute on Aging, a figure that has prompted the federal government to develop a series of training videos for police.

April 4, 2013

The annual cost of treating dementia in the United States ranges from $157 billion to $215 billion, according to a new study by the RAND Corp.

NEW YORK — The annual cost of treating dementia in the United States ranges from $157 billion to $215 billion, according to a new study by the RAND Corp.

The research organization said that number meant dementia costs more to treat than cancer or heart disease, with the greatest cost coming from institutional and home-based long-term care, as opposed to medical services.

December 7, 2012

Being mildly vitamin B-12 deficient could be an indication that some older adults are at a greater risk for accelerated cognitive decline, according to an observational study from researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University released Wednesday.

BOSTON — Being mildly vitamin B-12 deficient could be an indication that some older adults are at a greater risk for accelerated cognitive decline, according to an observational study from researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University released Wednesday.

April 6, 2012

Sam's Club is offering free screenings for brain health at all of its stores that operate pharmacies this month, the retailer said Friday.

BENTONVILLE, Ark. — Sam's Club is offering free screenings for brain health at all of its stores that operate pharmacies this month, the retailer said Friday.

The company, which has performed more than 1 million health and wellness screenings at it stores since 2011, said it would offer the screenings on April 14 for members and the public, including a memory test and educational materials on Alzheimer's and dementia provided by the Alzheimer's Foundation of America, as well as body mass index, blood pressure and glucose tests.

December 23, 2011

Drug maker Bristol-Myers Squibb and the Gladstone Institutes will collaborate to find new ways to treat Alzheimer's disease, the two said Thursday.

SAN FRANCISCO — Drug maker Bristol-Myers Squibb and the Gladstone Institutes will collaborate to find new ways to treat Alzheimer's disease, the two said Thursday.

November 11, 2011

Watson Pharmaceuticals is challenging Swiss drug maker Novartis' patent on a drug used to treat dementia, Watson said.

PARSIPPANY, N.J. — Watson Pharmaceuticals is challenging three of Swiss drug maker Novartis' patents on a drug used to treat dementia, Watson said.

The company said subsidiary Watson Labs had filed for approval generic rivastigmine transdermal system patches in the 4.6-mg and 9.5-mg strengths, both designed to last for 24 hours, with the Food and Drug Administration. The patches are used to treat mild to moderate dementia associated with Alzheimer's or Parkinson's disease.

September 21, 2011

A study published in the Sept. 20 issue of Neurology, the medical journal of the American Academy of Neurology, found a link between diabetes and the development of dementia.

NEW YORK — A study published in the Sept. 20 issue of Neurology, the medical journal of the American Academy of Neurology, found a link between diabetes and the development of dementia.

February 9, 2011

The National Advertising Division of the Council of Better Business Bureaus on Wednesday announced that Pharmavite is able to support advertising claims for the company’s NatureMade GreatMind dietary supplement, pursuant to NAD’s ongoing monitoring of advertising for dietary supplements.

NEW YORK — The National Advertising Division of the Council of Better Business Bureaus on Wednesday announced that Pharmavite is able to support advertising claims for the company’s NatureMade GreatMind dietary supplement, pursuant to NAD’s ongoing monitoring of advertising for dietary supplements.

NAD, the advertising industry’s self-regulatory forum, reviewed claims that appeared in print and Internet advertising and on product packaging, pursuant to NAD’s ongoing monitoring of advertising for dietary supplements.

January 5, 2011

BALTIMORE — If the government paid for drug cost incentives for Medicare patients with congestive heart failure, the program could recoup those costs and more by spending less on expensive hospitalizations for patients. 


That finding was one of several to emerge from research conducted by pharmacy students at the University of Maryland School of Pharmacy. The four students presented their findings on elderly drug adherence at the annual meeting of the Gerontology Society of America in New Orleans.

November 7, 2010

According to a study published in the November edition of Alzheimer’s & Dementia: The Journal...

WASHINGTON According to a study published in the November edition of Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, taking docosahexaenoic acid may improve memory and learning in older adults with mild cognitive impairments. The study found that DHA taken for six months improved memory and learning in healthy, older adults with mild memory complaints.

 

November 4, 2010

A daily dose of beet juice may increase blood flow to the brain and keep...

WINSTON-SALEM, N.C. A daily dose of beet juice may increase blood flow to the brain and keep the mind sharp, possibly helping to stave off dementia later in life, according to a new study.

Researchers at Wake Forest University found that beet juice is rich in nitrate, which the body converts into nitrite, a substance that helps open up blood vessels and improve blood flow. Nitrates also occur at high levels in celery, cabbage, spinach and some kinds of lettuce.

November 3, 2010

Nearly 100 drugs are in development for treating Alzheimer’s disease, according to a new report...

WASHINGTON Nearly 100 drugs are in development for treating Alzheimer’s disease, according to a new report by the main lobby for the pharmaceutical industry.

 

The Pharmaceutical Research and Manufacturers of America said 98 medicines for dementia, mostly Alzheimer’s, were in clinical trials or under review by the Food and Drug Administration.

 

 

October 29, 2010

SILVER SPRING , Md. (Oct. 29) The Food and Drug Administration has approved a new drug for treating schizophrenia, the agency said Thursday.

The FDA announced the approval of Latuda (lurasidone hydrochloride), made by Fort Lee, N.J.-based Sunovion Pharmaceuticals. The drug is approved to treat adults with the disease, a mental illness that causes hallucinations, delusions, paranoia and disordered thinking and behavior.

September 9, 2010

A small study conducted by Canadian researchers found factors that may link Type 2 diabetes...

WASHINGTON A small study conducted by Canadian researchers found factors that may link Type 2 diabetes with such cognitive impairments as dementia.

Older adults with diabetes who also have high blood pressure, walk slowly or lose their balance, or believe they’re in bad health, are more likely to have poorer cognitive functions than those without these problems, according to a new study conducted by researchers at the University of Alberta in Canada and published in the September issue of Neuropsychology

July 19, 2010

More than 300 medications for treating mental disorders are in development, according to a new...

WASHINGTON More than 300 medications for treating mental disorders are in development, according to a new report by a pharmaceutical industry lobbying group.

 

July 6, 2010

Sandoz has launched a version of a drug for treating dementia, the generics arm of...

July 5, 2010

Generic drug maker Caraco Pharmaceutical Labs has begun shipping a drug for treating dementia, Caraco...

June 30, 2010

Watson Pharmaceuticals has launched a generic version of a drug used to treat dementia under...

June 22, 2010

The Food and Drug Administration has approved a drug made by Forest Labs and Germany-based...

March 7, 2010

Diabetic adults with depression are twice as likely to develop dementia, according to a new...